PCSK9 antagonists and inflammation
Keywords: PCSK9; Inflammation;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis
Keywords: PCSK9; Acute coronary syndromes; Cardiovascular risk; Atherosclerosis; Carotid stenosis;
Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia
Keywords: Lipoprotein profile; 2D-1H-NMR; Heterozygous familial hypercholesterolaemia; Polygenic hypercholesterolaemia; Children; 2D-1H-NMR; two-dimensional nuclear magnetic resonance; CG; Control group; cIMT; carotid intima-media thickness; CCh; control children;
Small molecule modulators of PCSK9 - A literature and patent overview
Keywords: PCSK9; Modulator; Small molecules; LDL; Hypercholesterolemia;
PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent
Keywords: PCSK9; Lipid lowering; Lipoproteins; Low density lipoprotein cholesterol;
PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Keywords: PCSK9; Lipidomics; Lipoproteins; Atherosclerosis; Sphingolipids; Drug therapy; CAD; coronary artery disease; CE; cholesteryl ester; Cer; ceramide; DAG; diacylglycerol; Gb3; globotriasoylceramide; Glc/GalCer; glucosyl/galactosylceramide; GOF; gain-of-funct
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
Keywords: Atorvastatin; Diabetes mellitus; Lipoprotein(a); PCSK9; CETP;
PCSK9 inhibition in the management of familial hypercholesterolemia
Keywords: PCSK9; Familial hypercholesterolemia; Therapeutic target; Lipoprotein apheresis;
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome
Keywords: BMI; body mass index; CAD; Coronary artery disease; CHD; Coronary heart disease; HDLc; Cholesterol-high density lipoprotein cholesterol; HOMA-IR; Homeostatic model assessment for insulin resistance; HWE; Hardy-Weinberg equilibrium; LDLc; Cholesterol-low d
Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
Keywords: Familial hypercholesterolemia; Children; IDOL; LDLR; PCSK9; LDL; 2D-1H-NMR; Lp(a); Triglyceride;
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
Keywords: PCSK9; Evolocumab; Alirocumab; Cardiovascular outcomes; Safety;
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
Keywords: PCSK9; LDL-C; Familial hypercholesterolemia; Evolocumab; Monoclonal antibody; Safety;
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Keywords: Brain; Cholesterol; Cholesterol-lowering treatment; Neurocognitive function; PCSK9; PCSK9 inhibitors;
Overexpression of transforming growth factor β induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption
Keywords: Cholesterol metabolism; Lipoproteins; Liver; Transcription; Dyslipidemia; ABCA1; ATP-binding cassette transporter A1; ACAT2; acyl-Coenzyme A:cholesterol acyltransferase 2; apo; apolipoprotein; CYP7A1; cholesterol 7α-hydroxylase; HMGCR; 3-hydroxy-3-methyl
R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction
Keywords: Ankle-brachial index; Carotid atherosclerosis; Erectile dysfunction; Intima-media thickness; LDL-cholesterol; PCSK9; R46L;
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer
Keywords: Mitotane; Adrenocortical carcinoma; ACC; Hypercholesterolemia; PCSK9 inhibitors; PCSK9; Evolocumab;
Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves
Keywords: bioprosthesis; calcification; computed tomography; dysmetabolic; structural valve degeneration; AVR; aortic valve replacement; CI; confidence interval; CT; computed tomography; HDL; high-density lipoprotein; HOMA; homeostatic model assessment; HR; hazard
LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis
Keywords: LDL receptor; Golden Syrian hamster; Hyperlipidemia; Atherosclerosis; CRISPR/Cas9; ApoB; apolipoprotein B; ApoE; Apolipoprotein E; CETP; cholesteryl ester transfer protein; CAD; coronary artery disease; CD; chow diet; CHD; cardiovascular heart diseases; C
Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics
Keywords: Cardiometabolic diseases; Mass spectrometry; PCSK9; Posttranslational modifications; Quantitative proteomics; Bariatric surgery; LDL cholesterol; Triglycerides; Statin; Phosphorylation;
Proprotein Convertase Subtilisin Kexin 9 Inhibitors
Keywords: PCSK9; Monoclonal antibodies; Evolocumab; Alirocumab; LDL-C; Hypercholesterolemia; Cardiovascular disease; Proprotein convertase subtilisin kexin 9;
Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model
Keywords: GOF; gain of function; PCSK9; proprotein convertase subtilisin/kexin type-9; WT; wild-type; AD; atherogenic diet; MDCT; multidetector computed tomography; LDL-C; low-density lipoprotein cholesterol; ND; normal diet; IVUS; intravascular ultrasound; BOLD-MR
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)
Keywords: Alirocumab; PCSK9; LDL-C; South Korea; Taiwan; ODYSSEY phase 3; Hypercholesterolemia; Lipid lowering; Placebo-controlled; Maximally tolerated statin;
C679X loss-of-function PCSK9 variant lowers fasting glucose levels in a black South African population: A longitudinal study
Keywords: PCSK9; Type 2 diabetes; LDL-C; Loss of function; A443T; C679X; Black South African population;
Clinical Genetic Testing for Familial Hypercholesterolemia
Keywords: cascade testing; consensus statement; familial hypercholesterolemia; genetic counseling; genetic testing; ACMG; American College of Medical Genetics and Genomics; APOB; apolipoprotein B; CAD; coronary artery disease; DLCNC; Dutch Lipid Clinic Network Diag
A dual-type responsive electrochemical immunosensor for quantitative detection of PCSK9 based on n-C60-PdPt/N-GNRs and Pt-poly (methylene blue) nanocomposites
Keywords: Dual-type responsive electrochemical immunosensor; PCSK9; Pt-poly (methylene blue) nanocomposites; N-C60-PdPt; N-GNRs;
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A caseâcontrol study
Keywords: FH; familial hypercholesterolemia; LDLR; low-density lipoprotein receptor; APOB; apolipoprotein B; PCSK9; proprotein convertase subtilisin/kexin type 9; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein (a); ASCVD; atherosclerotic cardiovascu
AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice
Keywords: PCSK9; AAV8; Hypercholesterolemia; Atherosclerosis;
Diagnosis and therapy with CRISPR advanced CRISPR based tools for point of care diagnostics and early therapies
Keywords: CRISPR; clustered regularly interspaced short palindromic repeats; Cas; CRISPR-associated protein; crRNA; CRISPR RNA; SgRNA; single guide RNA; tracrRNA; trans-activating RNA; PAM; protospacer-adjacent motif; DSB; DNA double strand break; SHERLOCK; Specifi
Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
Keywords: PCSK9; Triglycerides; Lipoproteins; Metabolism; Monoclonal antibodies;
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
Keywords: PCSK9; LDL-cholesterol; Liver steatosis; Liver fibrosis; MRI; Liver biopsy;
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Keywords: PCSK9; Alirocumab; Cholesterol-lowering drugs; Low-density lipoprotein cholesterol; Coronary revascularization; Cardiovascular risk;
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
Keywords: ACAT; Acyl-CoA:cholesterol acyltransferase; ADAM17; a disintegrin and metalloproteinase 17; APO; apolipoprotein; COL18; collagen XVIII; CS/DS; chondroitin sulfate/dermatan sulfate; FLOT1; flotilin-1; GLCE; C5 epimerase; GPIHBP1; glycosylphosphatidylinosit
PCSK9-related LDL-C value is correlated to Rab5 isoform expression level
Keywords: CVD; cardiovascular diseases; TGN; trans-Golgi network; MPRs; mannose 6-phosphate receptors; PCSK9; proprotein convertase subtilisin/kexin type 9; LDLR; LDL receptor; LAMP1; lysosomal associated membrane protein 1; LAMP2; lysosomal associated membrane pro
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females
Keywords: PCSK9; Metabolic syndrome; Insulin resistance; Dyslipidemia;
Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease
Keywords: Coronary artery disease; Cholesterol metabolism; PCSK9; Sortilin;
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease
Keywords: Dyslipidemia; Hypocholesterolemia; Hypobetalipoproteinemia; Liver steatosis; PCSK9; Proprotein convertase subtilisin/kexin type 9; PNPLA3; TM6SF2; Nonalcoholic fatty liver disease;
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Keywords: PCSK9; Cholesterol efflux; ABCA1; Macrophage;
Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA
Keywords: PCSK9; proprotein convertase subtilisin/kexin type 9; rPCSK9; recombinant PCSK9; ELISA; enzyme-linked immunosorbent assay; LDL; low-density lipoprotein; LDL-C; LDL cholesterol; AB; ammonium bicarbonate; DTT; dithiotreitol; IA; iodoacetamide; SDC; sodium d
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
Keywords: Mus spretus; PCSK9; Genetic variation; LDLR; Lipoprotein; Cholesterol; Promoter;
APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo
Keywords: PCSK9; proprotein convertase subtilisin/kexin type 9; LDLR; low-density lipoprotein receptor; APP; amyloid precursor protein; APLP2; amyloid precursor-like protein 2; LRP1; LDL receptor-related protein 1; DSP; dithiobis[succinimidylpropionate]; SDA; (succ
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism
Keywords: PCSK9; LDL cholesterol; Triglycerides; Chronic kidney disease; eGFR;
The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
Keywords: Atherosclerosis; CVD; Sirtuin; SIRT1; SIRT3; SIRT6; Oxidative stress; Lipid metabolism; ABC; Adenosine triphosphate binding cassette; ABCG; ABC sub-family G member; ADP; Adenosine diphosphate; AMPK; Adenosine monophosphate-activated protein kinase; eNOS;
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study
Keywords: Familial hypercholesterolemia; LDLR; PCSK9; APOB; Pathogenic variants;
Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
Keywords: FOH; farnesol; GGOH; geranylgeraniol; HMG-CoA; 3-hydroxy-3-methyl-3-glutaryl coenzyme A; MVA; mevalonate; LDL-C; low-density lipoprotein cholesterol; LPDS; lipoprotein plasma-deprived serum; PCSK9; proprotein convertase subtilisin/kexin type 9; SOCS3; sup
PCSK9 Inhibitors Show Value for Patients and the US Health Care System
Keywords: alirocumab; cardiovascular disease; cholesterol; evolocumab; familial hypercholesterolemia; microsimulation; PCSK9;
The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Keywords: ApoB/ApoA-I; Apolipoprotein B/Apolipoprotein A-I; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; CI; Confidence interval; CVD; Cardiovascular disease; CHD; Coronary heart disease; AMG 145; Evolocumab; Q2W; Every 2Â weeks; Q4W; Every 4Â we
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Keywords: PCSK9; Atherosclerosis; Inflammation; Macrophage; TLR4/ /NF-κB;
Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression
Keywords: SCH; subclinical hypothyroidism; TC; total cholesterol; LDL-c; low-density lipoprotein cholesterol; TSH; thyroid stimulating hormone; TSHR; thyroid stimulating hormone receptor; HMGCR; 3-hydroxy-3-methylglutaryl-CoA reductase; PCSK9; proprotein convertase
Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis
Keywords: LDL cholesterol; LDL receptor; Neoagarooligosaccharides; PCSK9; SREBP-2; ALT; alanine aminotransferase; AOS; agaro-oligosaccharides; AST; aspartate aminotransferase; CHD; coronary heart disease; DNS; dinitrosalicylic acid; DP; degree of polymerization; HC